NEOADJUVANT TREATMENT OF LOCALLY ADVANCED ER, PR AND HER-2 POSITIVE BREAST CANCER- A CASE REPORT
Anjaly P. Nair, Anjali Krishnan K., Lakshmi R.*, Siby Joseph, C. S. Madhu and Sanjay Mukundan
Breast cancer expressing all three diagnostic markers (estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)) is insufficiently characterized even though it is present currently in the patient population. Near 75% of all breast cancers (BC) express ER and/ PR, while only up to 20% of BC show an overexpression or amplification of HER2. Around 50% of all HER2-overexpressing BC show the coexistence of both ER and/ PR overexpression. Here we discuss a case of 51 years old female who was diagnosed with infiltrating duct carcinoma having receptor positivity only to ER and PR initially and on relapse was found to be triple positive and had a greater response to treatment with antiestrogen and anti HER 2 therapies.
Keywords: Metachronous BC, Triple Positive, Breast Cancer, HER-2 Neu receptor, Endometrial hyperplasia.
[Full Text Article]